Inhibition of abnormal ERK activities in these cancer cells by canertinib (an EGFR inhibitor), vemurafenib (a BRaf inhibitor), or trametinib (a MEK inhibitor) treatment abrogated their expression (Fig. 7e). The gene discussed is MAPK1; the disease is cancer.